Trochanteric bursitis after total hip arthroplasty: incidence and evaluation of response to treatment

J Arthroplasty. 2010 Feb;25(2):208-12. doi: 10.1016/j.arth.2009.02.008. Epub 2009 Mar 4.

Abstract

We examined the efficacy of corticosteroid injection as treatment for postarthroplasty trochanteric bursitis and the risk factors for failure of nonoperative treatment. There were 32 (4.6%) cases of postsurgical trochanteric bursitis in 689 primary total hip arthroplasties. Of the 25 hips with follow-up, 11 (45%) required multiple injections. Symptoms resolved in 20 (80%) but persisted in 5. We found no statistically significant differences between patients who did and did not develop trochanteric bursitis, or between those who did and did not respond to treatment. There was a trend toward younger age and greater limb-length discrepancy in nonresponders. In conclusion, (1) corticosteroid injection(s) for postoperative trochanteric bursitis is effective; and (2) nonoperative management may be more likely to fail in young patients and those with leg-length discrepancy.

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Arthralgia / drug therapy
  • Arthralgia / epidemiology
  • Arthralgia / etiology
  • Arthroplasty, Replacement, Hip / adverse effects*
  • Bursitis / drug therapy*
  • Bursitis / epidemiology
  • Bursitis / etiology*
  • Female
  • Femur*
  • Hip Joint*
  • Humans
  • Incidence
  • Injections, Intra-Articular
  • Male
  • Middle Aged
  • Osteoarthritis, Hip / surgery
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones